첨단 약물전달 시스템 시장(2026-2030년)

The global advanced drug delivery systems market is forecasted to grow by USD 258396.4 mn during 2025-2030, accelerating at a CAGR of 12.4% during the forecast period. The report on the global advanced drug delivery systems market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of chronic and complex diseases, increasing development and commercialization of biologics and specialty therapeutics, rising focus on patient centric treatment experiences.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global advanced drug delivery systems market is segmented as below:

By Type

• Oral
• Injection and inhalation
• Transdermal
• Carrier-based
• Others

By Application

• Oncology
• Cardiovascular diseases
• Infectious diseases
• Neurology/CNS disorders
• Others

By End-User

• Hospitals
• Specialty clinics
• Research and development centers
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the expansion of wearable drug administration solutions as one of the prime reasons driving the global advanced drug delivery systems market growth during the next few years. Also, growing adoption of decentralized treatment delivery models and rising emphasis on sustainability within delivery system design will lead to sizable demand in the market.

The report on the global advanced drug delivery systems market covers the following areas:

• Global advanced drug delivery systems market sizing
• Global advanced drug delivery systems market forecast
• Global advanced drug delivery systems market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global advanced drug delivery systems market vendors that include AptarGroup Inc., Becton Dickinson and Co., Catalent Inc., Evonik Industries AG, Gerresheimer AG, Halozyme Therapeutics Inc., InnoCore Pharmaceuticals, InventaGel Labs, Lonza Group Ltd., LTS Lohmann Therapie Systeme AG, Nanotech Pharma, Nemera Group, Nitto Denko Corp., Oakwood Labs, Phillips Medisize, Phosphorex Inc., PolyMicrospheres, Recipharm AB, Stevanato Group S.p.A, West Pharma Services Inc.. Also, the global advanced drug delivery systems market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Advanced Drug Delivery Systems Market 2020 - 2024
  • Historic Market Size - Data Table on Global Advanced Drug Delivery Systems Market 2020 - 2024 ($ million)
• 5.2 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.3 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
• 5.4 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global advanced drug delivery systems market
• 6.2 Impact of geopolitical conflicts on global advanced drug delivery systems market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Type

• 8.1 Market segments
• 8.2 Comparison by Type
• 8.3 Oral - Market size and forecast 2025-2030
• 8.4 Injection and inhalation - Market size and forecast 2025-2030
• 8.5 Transdermal - Market size and forecast 2025-2030
• 8.6 Carrier-based - Market size and forecast 2025-2030
• 8.7 Others - Market size and forecast 2025-2030
• 8.8 Market opportunity by Type
  • Market opportunity by Type ($ million)

9 Market Segmentation by Application

• 9.1 Market segments
• 9.2 Comparison by Application
• 9.3 Oncology - Market size and forecast 2025-2030
• 9.4 Cardiovascular diseases - Market size and forecast 2025-2030
• 9.5 Infectious diseases - Market size and forecast 2025-2030
• 9.6 Neurology/CNS disorders - Market size and forecast 2025-2030
• 9.7 Others - Market size and forecast 2025-2030
• 9.8 Market opportunity by Application
  • Market opportunity by Application ($ million)

10 Market Segmentation by End-user

• 10.1 Market segments
• 10.2 Comparison by End-user
• 10.3 Hospitals - Market size and forecast 2025-2030
• 10.4 Specialty clinics - Market size and forecast 2025-2030
• 10.5 Research and development centers - Market size and forecast 2025-2030
• 10.6 Others - Market size and forecast 2025-2030
• 10.7 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 South Africa - Market size and forecast 2025-2030
  • 12.6.7 Colombia - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Growing prevalence of chronic and complex diseases
  • Increasing development and commercialization of biologics and specialty therapeutics
  • Rising focus on patient centric treatment experiences
• 13.2 Market challenges
  • Regulatory complexity and approval delays
  • High manufacturing complexity and production scalability limitations
  • Patient adoption barriers and healthcare system integration difficulties
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Expansion of wearable drug administration solutions
  • Growing adoption of decentralized treatment delivery models
  • Rising emphasis on sustainability within delivery system design

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AptarGroup Inc.
  • AptarGroup Inc. - Overview
  • AptarGroup Inc. - Business segments
  • AptarGroup Inc. - Key news
  • AptarGroup Inc. - Key offerings
  • AptarGroup Inc. - Segment focus
  • SWOT
• 15.5 Becton Dickinson and Co.
  • Becton Dickinson and Co. - Overview
  • Becton Dickinson and Co. - Business segments
  • Becton Dickinson and Co. - Key news
  • Becton Dickinson and Co. - Key offerings
  • Becton Dickinson and Co. - Segment focus
  • SWOT
• 15.6 Catalent Inc.
  • Catalent Inc. - Overview
  • Catalent Inc. - Product / Service
  • Catalent Inc. - Key offerings
  • SWOT
• 15.7 Evonik Industries AG
  • Evonik Industries AG - Overview
  • Evonik Industries AG - Business segments
  • Evonik Industries AG - Key news
  • Evonik Industries AG - Key offerings
  • Evonik Industries AG - Segment focus
  • SWOT
• 15.8 Gerresheimer AG
  • Gerresheimer AG - Overview
  • Gerresheimer AG - Business segments
  • Gerresheimer AG - Key offerings
  • Gerresheimer AG - Segment focus
  • SWOT
• 15.9 Halozyme Therapeutics Inc.
  • Halozyme Therapeutics Inc. - Overview
  • Halozyme Therapeutics Inc. - Product / Service
  • Halozyme Therapeutics Inc. - Key offerings
  • SWOT
• 15.10 InnoCore Pharmaceuticals
  • InnoCore Pharmaceuticals - Overview
  • InnoCore Pharmaceuticals - Product / Service
  • InnoCore Pharmaceuticals - Key offerings
  • SWOT
• 15.11 InventaGel Labs
  • InventaGel Labs - Overview
  • InventaGel Labs - Product / Service
  • InventaGel Labs - Key offerings
  • SWOT
• 15.12 Lonza Group Ltd.
  • Lonza Group Ltd. - Overview
  • Lonza Group Ltd. - Business segments
  • Lonza Group Ltd. - Key news
  • Lonza Group Ltd. - Key offerings
  • Lonza Group Ltd. - Segment focus
  • SWOT
• 15.13 LTS Lohmann Therapie Systeme AG
  • LTS Lohmann Therapie Systeme AG - Overview
  • LTS Lohmann Therapie Systeme AG - Product / Service
  • LTS Lohmann Therapie Systeme AG - Key offerings
  • SWOT
• 15.14 Nanotech Pharma
  • Nanotech Pharma - Overview
  • Nanotech Pharma - Product / Service
  • Nanotech Pharma - Key offerings
  • SWOT
• 15.15 Nemera Group
  • Nemera Group - Overview
  • Nemera Group - Product / Service
  • Nemera Group - Key offerings
  • SWOT
• 15.16 Nitto Denko Corp.
  • Nitto Denko Corp. - Overview
  • Nitto Denko Corp. - Business segments
  • Nitto Denko Corp. - Key offerings
  • Nitto Denko Corp. - Segment focus
  • SWOT
• 15.17 Stevanato Group S.p.A
  • Stevanato Group S.p.A - Overview
  • Stevanato Group S.p.A - Product / Service
  • Stevanato Group S.p.A - Key offerings
  • SWOT
• 15.18 West Pharma Services Inc.
  • West Pharma Services Inc. - Overview
  • West Pharma Services Inc. - Business segments
  • West Pharma Services Inc. - Key offerings
  • West Pharma Services Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations